Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Bullboard Posts
Comment by DuncinMcCon Sep 21, 2018 10:55am
94 Views
Post# 28663853

RE:RE:RE:share price reduction

RE:RE:RE:share price reduction Hey MrMarket and the other 3 or four posters, 

It has been a while since posting, and I am rather frustrated with the SP as well.  Down half my investment, and daily think about taking the loss and reinvesting in MJ, but can't seem to pull the trigger.  

My sense of the sells which have pulled us down recently is the lack of news from the board about the single arm study and communications with FDA team.  

Just a few days ago, I went back through the investor PP and still feel that the potential of the result of this next step is very good, but the SP does not reflect that.  MM has made some great posts about this information a month or so ago. 

The way I see it is, we saw some potential with very specialized treatment of a subsect of sepsis patients.  This has yet to be clearly demonstrated to the FDA so they asked for another short study and further evidence to help verify the specialized treatment, as our double blind blah blah was not focused on that.  

If the FDA is very eager to get a solution to some of the deaths with sepsis, which many of the quotes expressed on this board would verify and if they have said to the company - complete a simple, and quick study focused solely on an area that has proven through secondary endpoints is potentially effective then resubmit - I would say the future is promising.  

The company is terrible with stockholder communication - they really could give two Sh!ts about us, and often I feel their estimates of timelines tend to be optimistic.  With that said, they have mentioned officially they are still communicating with FDA and that they expect the single arm study to be relatively short in timeline - holding for another year still seems to be fine for me. 

Ultimately, I have been holding long for this anywho.  I should have dumped half when it was close to 2 dollars, and rebought, but greed got the best of me.  Im a young investor, so I am still figuring things out.  

I do appreciate MM's thoughtful and thorough updates, and breakdowns.   Hope that gives you some hope.  

DMcC
Bullboard Posts